Ian Churcher

Ian Churcher is an accomplished leader in the field of drug discovery and development, currently serving as an Advisory Board Member at Arvinas and VantAI, and as Chief Executive Officer at Janus Drug Discovery Consulting Ltd. Previously, Ian held significant roles, including Chief Technology Officer and Chief Scientific Officer at Amphista Therapeutics Limited, where the focus was on next-generation protein degradation projects. Ian's career includes substantial contributions at BenevolentAI as Senior Vice President of Drug Discovery and as Head of the Protein Degradation Discovery Performance Unit at GlaxoSmithKline. Educationally, Ian obtained a D.Phil in Organic Chemistry from the University of Oxford and completed a postdoctoral fellowship at The University of Texas at Austin.